Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

2021; Lippincott Williams & Wilkins; Volume: 39; Issue: 13 Linguagem: Inglês

10.1200/jco.20.03399

ISSN

1527-7755

Autores

Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey, Jennie R. Crews, Neelima Denduluri, E. Shelley Hwang, Seema A. Khan, Sibylle Loibl, Elizabeth A. Morris, Alejandra Perez, Meredith M. Regan, Patricia A. Spears, Preeti Sudheendra, W. Fraser Symmans, Rachel L. Yung, Brittany Harvey, Dawn L. Hershman,

Tópico(s)

HER2/EGFR in Cancer Research

Resumo

To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.

Referência(s)